US9216591084 - VNDA - A0JJT3 (XNMS)
VANDA PHARMACEUTICALS INC Aktie
4,65 USD
Aktuelle Kurse von VANDA PHARMACEUTICALS INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
VNDA
|
USD
|
20.09.2024 01:54
|
4,65 USD
| 4,95 USD | -6,08 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | -9,73 % | -12,52 % | -26,67 % | 23,64 % | 5,90 % | -65,56 % |
Firmenprofil zu VANDA PHARMACEUTICALS INC Aktie
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Investierte Fonds
Folgende Fonds haben in VANDA PHARMACEUTICALS INC investiert:
Fonds | Vol. in Mio 29,72 | Anteil (%) 0,07 % |
Unternehmensdaten zur VANDA PHARMACEUTICALS INC Aktie
Name VANDA PHARMACEUTICALS INC
Firma Vanda Pharmaceuticals Inc.
Symbol VNDA
Website https://www.vandapharma.com
Heimatbörse
NASDAQ/NMS (GLOBAL MARKET)
WKN A0JJT3
ISIN US9216591084
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Mihael H. Polymeropoulos M.D.
Marktkapitalisierung 293 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,2 T
Adresse 2200 Pennsylvania Avenue NW, 20037 Washington
IPO Datum 2006-04-12
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | VM4.F |
NASDAQ | VNDA |
Weitere Aktien
Investoren die VANDA PHARMACEUTICALS INC halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024